Envoy Medical Inc（COCH）资讯与事件COCHEnvoy Medical Inc

Envoy Medical Files to Sell Class A Common Stock

Envoy Medical files to sell Class A common stock, no amount given

Envoy Medical reports Q3 EPS (37c) vs. 13c last year.

Reports Q3 revenue $56,000 vs. $80,000 last year. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim fully implanted cochlear implant. Second, we continue to make tremendous progress on obtaining meaningful reimbursement for our already FDA-approved Esteem FIAMEI. We continue to receive considerable support for the bipartisan bills that were introduced in both the House and the Senate this year to change the way fully implanted active middle ear hearing devices classified by CMS. In addition, the American Medical Association's CPT Editorial Panel has approved Category III CPT codes for totally implantable active middle ear hearing devices for the first time. A significant step forward for our Esteem device. Ultimately, we continue to believe that our products are important innovations for patients suffering from hearing loss and foresee a bright future for Envoy Medical," commented Brent Lucas, Envoy Medical's Chief Executive Officer. "We look forward to updating shareholders on our progress as we initiate the trial for the Acclaim(R) device and as we progress with our reimbursement strategy for the Esteem device."